<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007262</url>
  </required_header>
  <id_info>
    <org_study_id>TNTL-21-01</org_study_id>
    <nct_id>NCT05007262</nct_id>
  </id_info>
  <brief_title>Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy</brief_title>
  <official_title>Clinical Study on the Efficacy and Safety of Tangningtongluo Tablet in Treating Non Proliferative Diabetic Retinopathy - The Syndrome of Yin Asthenia Generating Intrinsic Heat and Eye Collateral Stasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guizhou Bailing Group Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guizhou Bailing Group Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is planned to collect relevant clinical data to evaluate the prevention efficacy&#xD;
      and safety of Tangningtongluo tablets on the non-proliferation period of diabetic&#xD;
      retinopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks,all patients giving written informed&#xD;
      consent will undergo a 1-week screening period to eligibility for study entry.At week&#xD;
      0,patients who meet the eligibility requirements will be randomized into two&#xD;
      groups(experimental group and control group)in a 1:1 ratio to Tangningtongluo tablets(4&#xD;
      tablets,tid,po.) or Calcium dobesilate capsules(1 capsule,tid,po.).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">March 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected vision acuity (BCVA)</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>using ETDRS vision chart measure vision change from Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>diabetic retinopathy(DR)progression rate</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>Using ETDRS Classification to evaluate DR Progress rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fundus photography</measure>
    <time_frame>At 12, 24weeks</time_frame>
    <description>quantitative analysis of fundus microhemangioma, bleeding, exudation, and tube diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal blood oxygen saturation</measure>
    <time_frame>At 12, 24weeks</time_frame>
    <description>measure retinal blood oxygen saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal macular optical coherence tomography angiography (OCTA)</measure>
    <time_frame>At 12, 24weeks</time_frame>
    <description>measure macular vascular density, retinal thickness, retinal volume;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>At 12,24,36 and 48 weeks</time_frame>
    <description>Measure the patient's HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine eye examination;</measure>
    <time_frame>At 4,8,12, 24,36 and 48 weeks</time_frame>
    <description>Including the examination of cornea, lens, anterior chamber, iris, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of traditional Chinese medicine syndrome.</measure>
    <time_frame>At 12, 24 and 48 weeks</time_frame>
    <description>It includes the evaluation of the main symptoms such as blurred vision, dry eyes, secondary symptoms such as mental fatigue, shortness of breath and lazy speech, dry mouth and dry throat and etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Tangningtongluo tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tangningtongluo tablets, 4 tablets one time,tid,po, taken after meals.The patients will receive drugs for 24 weeks continuously. After 24 weeks, the researchers will decide whether to continue depend on the patient condition and willingness. The maximum medication time is up to 48 weeks.Basic treatment: According to the comprehensive objectives of China Type 2 Diabetes Guidelines (2020 Edition) .The Angiotensin-Converting Enzyme（ACEI） and Angiotensin Receptor Blocker（ARB） drugs will be continued to use as the original treatment protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium dobesilate capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcium dobesilate capsules, 1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.After 24 weeks, the researchers will decide whether to continue depend on the patient condition and willingness. The maximum medication time is up to 48 weeks.Basic treatment: According to the comprehensive objectives of China Type 2 Diabetes Guidelines (2020 Edition) .The Angiotensin-Converting Enzyme（ACEI ）and Angiotensin Receptor Blocker （ARB） drugs will be continued to use as the original treatment protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tangningtongluo tablets</intervention_name>
    <description>Four pills each time and three times a day after meals.</description>
    <arm_group_label>Tangningtongluo tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium dobesilate capsules</intervention_name>
    <description>1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.</description>
    <arm_group_label>Calcium dobesilate capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Patients with the diagnosis of type 2 diabetes.&#xD;
&#xD;
          -  2. Patients with the diagnosis of non-proliferative diabetic retinopathy and the&#xD;
             classified as mild and moderate.&#xD;
&#xD;
          -  3. Target eye best corrected vision acuity (BCVA) ≥ 34 points (ETDRS vision chart,&#xD;
             vision equivalent of score 20 / 200, decimal 0.1).&#xD;
&#xD;
          -  4. Patients who meet the syndrome differentiation standards of yin asthenia generating&#xD;
             intrinsic heat and eye collateral stasis in traditional Chinese medicine.&#xD;
&#xD;
          -  5. HbA1C ≤ 9%.&#xD;
&#xD;
          -  6. Age between 18 and 75 years old&#xD;
&#xD;
          -  7. Informed consent, voluntary subject. The process of obtaining informed consent form&#xD;
             complies with Good Clinical Practice(GCP).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patient with the diagnosis of diabetic retinopathy is combined with severe vitreous&#xD;
             blood effusion, or required total retinal laser treatment or vitrectomy.&#xD;
&#xD;
          -  2. Patient who has been treated with full retinal laser photocoagulation.&#xD;
&#xD;
          -  3. Patient with difficulty in evaluating fundus images with refractive medium&#xD;
             turbidity.&#xD;
&#xD;
          -  4. Patient was diagnosed of acute metabolic disorders such as diabetic ketoacidosis or&#xD;
             combined with severe acute infection in the past 1 month.&#xD;
&#xD;
          -  5. Patient with other serious diabetes complications, such as diabetes gangrene.&#xD;
&#xD;
          -  6. Patient was allergic to Tangningtongluo tablets, or Calcium dobesilate, or its&#xD;
             composition.&#xD;
&#xD;
          -  7. Female patient with pregnancy, or prepare for pregnancy, or lactating.&#xD;
&#xD;
          -  8. Patient with serious cardiovascular, liver, kidney or hematopoietic system disease,&#xD;
             and mental diseases.&#xD;
&#xD;
          -  9. Liver and renal function (Alanine aminotransferase (ALT) or Aspartate&#xD;
             aminotransferase (AST) above 2 x Upper limit of normal (ULN)and Cr&gt; above 1 x Upper&#xD;
             limit of normal (ULN)). The diabetic nephropathy stage was 4 and above.&#xD;
&#xD;
          -  10. Patient with eye diseases such as glaucoma, uveitis, optic neuropathy, and severe&#xD;
             cataract.&#xD;
&#xD;
          -  11. Patient participated in other clinical researches within a month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junguo Duan, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ineye Hospital of Chendu University of TCM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junguo Duan, professor</last_name>
    <phone>+86-13808048959</phone>
    <email>duanjgs@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ineye Hospital of Chendu University of TCM</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuwen Zhang, Researcher</last_name>
      <phone>+86-18980880199</phone>
      <email>330920118@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Retinopathy</keyword>
  <keyword>Tangningtongluo tablets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium Dobesilate</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

